Goldman Sachs
BLFS icon

Goldman Sachs’s BioLife Solutions BLFS Stock Holding History

Goldman Sachs’s Portfolio BLFS Stock Details BLFS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.07M Buy
265,487
+36,546
+16% +$808K ﹤0.01% 3678
2025
Q4 		$5.54M Buy
228,941
+47,222
+26% +$1.24M ﹤0.01% 3659
2025
Q3 		$4.64M Buy
181,719
+58,965
+48% +$1.4M ﹤0.01% 3721
2025
Q2 		$2.64M Sell
122,754
-222,794
-64% -$5.02M ﹤0.01% 3962
2025
Q1 		$7.89M Sell
345,548
-32,600
-9% -$858K ﹤0.01% 2913
2024
Q4 		$9.82M Buy
378,148
+184,231
+95% +$4.58M ﹤0.01% 2830
2024
Q3 		$4.86M Buy
193,917
+77,225
+66% +$1.82M ﹤0.01% 3367
2024
Q2 		$2.5M Sell
116,692
-30,646
-21% -$595K ﹤0.01% 3760
2024
Q1 		$2.73M Sell
147,338
-2,254,561
-94% -$39.4M ﹤0.01% 3620
2023
Q4 		$39M Buy
2,401,899
+2,191,002
+1,039% +$28M 0.01% 1358
2023
Q3 		$2.91M Buy
210,897
+103,612
+97% +$1.63M ﹤0.01% 3461
2023
Q2 		$2.37M Sell
107,285
-14,232
-12% -$300K ﹤0.01% 3737
2023
Q1 		$2.64M Buy
121,517
+10,224
+9% +$230K ﹤0.01% 3631
2022
Q4 		$2.03M Sell
111,293
-22
-0% -$454 ﹤0.01% 3940
2022
Q3 		$2.53M Buy
111,315
+32,444
+41% +$694K ﹤0.01% 3767
2022
Q2 		$1.09M Buy
78,871
+5,414
+7% +$79.4K ﹤0.01% 4541
2022
Q1 		$1.67M Buy
73,457
+8,066
+12% +$212K ﹤0.01% 4396
2021
Q4 		$2.44M Sell
65,391
-65,709
-50% -$2.82M ﹤0.01% 4087
2021
Q3 		$5.55M Buy
131,100
+96,701
+281% +$4.66M ﹤0.01% 3275
2021
Q2 		$1.53M Buy
34,399
+3,062
+10% +$108K ﹤0.01% 4433
2021
Q1 		$1.13M Buy
31,337
+11,909
+61% +$471K ﹤0.01% 4508
2020
Q4 		$775K Sell
19,428
-19,538
-50% -$666K ﹤0.01% 4354
2020
Q3 		$1.13M Buy
38,966
+2,639
+7% +$57K ﹤0.01% 3989
2020
Q2 		$594K Buy
+36,327
New +$501K ﹤0.01% 4277
2020
Q1 		– Sell
-43,402
Closed -$702K – 5212
2019
Q4 		$702K Buy
43,402
+32,031
+282% +$521K ﹤0.01% 4326
2019
Q3 		$189K Buy
+11,371
New +$213K ﹤0.01% 4838
2019
Q2 		– Sell
-69,692
Closed -$1.25M – 5137
2019
Q1 		$1.25M Buy
+69,692
New +$1.11M ﹤0.01% 3935

Other funds holding BLFS

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs's BLFS Position: Q1 2026 in Review

Goldman Sachs increased its BioLife Solutions (BLFS) stake by 16% in Q1 2026, buying an estimated $808K and bringing the position to 265,487 shares worth $5.07M. The position accounts for ﹤0.01% of the portfolio, ranked #3678.

Goldman Sachs first reported a position in BLFS in Q1 2019 and has held it in 27 quarters since. The position peaked at $39M in Q4 2023. 187 funds tracked by Wall St. Rank hold BLFS as of Q1 2026.

  • Goldman Sachs held 265,487 shares of BioLife Solutions worth $5.07M as of Q1 2026.
  • Goldman Sachs bought 36,546 BioLife Solutions shares in Q1 2026, an estimated $808K.
  • BioLife Solutions made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #3678 holding.
  • Goldman Sachs first reported a position in BioLife Solutions in Q1 2019 and has held it in 27 quarters since.
  • Goldman Sachs's BioLife Solutions position peaked at $39M in Q4 2023.
  • 187 funds tracked by Wall St. Rank held BioLife Solutions as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.